From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.

This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases. Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research.

This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases.  Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.

This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases. Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research.

This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases.  Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research.

This book considers chronic obstructive pulmonary disease (COPD) not as a simple inflammation of the lung but as a systemic inflammatory disease. Beginning with epidemiological studies, etiology, diagnosis and treatment, it elaborates further, illustrating some comorbidities and associations with other respiratory diseases. As such it provides numerous improved and more comprehensive treatment methods, including drug therapies as well as some non-drug therapies.  There are also chapters describing the pathogenesis, genetic abnormalities and newly discovered pathogenetic mechanisms that are expected to be studied further in the future.Edited and written by pioneering researchers, each chapter summarizes the latest trends, describes future prospects and explores the unresolved and critical questions. Chronic Obstructive Pulmonary Disease - A Systemic Inflammatory Disease is a valuable resource to beginning researchers, physicians engaged in clinical practice, supervisors, and basic researchers whose work includes COPD.